NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ --

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation  at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia.

ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations.

Details on the Presentations are as follows:

Title: Constant Therapeutic Levodopa Plasma Concentrations Maintained by Continuous Subcutaneous Administration of ND−0612, a Novel Formulation of Levodopa/Carbidopa
Abstract #: 452
Presenter: Peter LeWitt
Poster session: Parkinson's Disease: Clinical Trials
Date and time: Tuesday, June 18th, 12:30pm
Location: Bayside, level, 1 gallery B

Title: ND0612, A Novel Formulation of Levodopa/Carbidopa for Continuous, Subcutaneous Administration, Achieves Steady-State Levodopa Plasma Concentrations in Parkinson's Disease Patients
Abstract #: LBA26
Presenter: Nir Giladi
Poster session: Late Breaking Abstracts
Date and time: Wednesday, June 19th, 12:00pm
Location: Exhibit hall #5

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well-established oral drugs that achieve better efficacy. The company's lead products are ND0612, a novel sub-cutaneous drug formulation for the treatment of Parkinson's disease, and ND0801, a combination drug for the treatment of cognitive disorders in diseases such as ADD/ADHD, schizophrenia and Alzheimer's disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact:
Oded S. Lieberman, PhD MBA, Chairman & CEO
oded@neuroderm.com
Tel.: +972-8-946 2729; Cell: +1-617-517-6077

SOURCE NeuroDerm Ltd



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.